Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its oral investigational drug for atopic dermatitis.Soquelitinib demonstrated strong efficacy in treatment-resistant patients and a “favourable” safety profile, sparking chatter about “best-in-class” potential in the massive dermatology market.Following today’s…
Netflix (NASDAQ: NFLX) shares are trending down in after-hours after the streaming behemoth reported its financials for the fourth…
Silver’s rapid price surge is rippling through global markets, straining supply chains and forcing banks and refiners to scramble…
Asian financial markets remained under pressure on Wednesday as geopolitical tensions linked to US President Donald Trump’s comments on…
UK inflation rose for the first time in five months in December, adding to expectations that the Bank of…
Canadian Prime Minister Mark Carney warned that the postwar global order led by the United States is breaking down,…
Chocolate and cocoa giant Barry Callebaut announced Wednesday that it has named former Unilever CEO Hein Schumacher as its…
Japan has restarted a nuclear reactor at the world’s largest atomic power plant for the first time since the…
If tensions continue to escalate and the dollar remains weak, gold prices could soon hit the coveted $5,000 per…